Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 Follicular Thyroid Carcinoma:A Retrospective Propensity Score-Matched Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06437873

Enrollment

2957

Registered

2024-05-31

Start date

2000-01-01

Completion date

2024-05-25

Last updated

2024-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Thyroid Cancer, SEER Database Analysis

Keywords

Retrospective analysis, follicular thyroid carcinoma, total thyroidectomy, long-term survival outcomes.

Brief summary

This study aims to thoroughly examine survival disparities in patients with T3 or T4 stage follicular thyroid carcinoma (FTC) as classified by the AJCC staging system. It compares outcomes between those who underwent total thyroidectomy (TT) and those who did not, and assesses the influence of radioactive iodine therapy (RAIT) on the survival of patients without TT. Utilizing the SEER database, a retrospective study identified patients diagnosed with T3 or T4 FTC, categorizing them into two cohorts: those treated with TT and those who were not (No-TT). The No-TT group was further analyzed to determine the impact of RAIT on patient survival. Propensity score matching (PSM) was applied to adjust for confounding variables. Survival analysis, including Kaplan-Meier survival curves and Landmark analysis, was conducted to evaluate the effects of surgical intervention and RAIT on overall survival (OS) and cancer-specific survival (CSS).

Interventions

PROCEDURETotal Thyroidectomy (TT)

TT:Surgical removal of the entire thyroid gland.

RADIATIONRadioactive iodine treatment(RAIT)

RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

1.The primary site code C73.9, denoting the thyroid gland;2.The International Classification of Diseases for Oncology, Third Edition (ICD-O-3) histology types comprising 8330 (Follicular adenocarcinoma, NOS), 8331 (Follicular adenocarcinoma well differentiated), 8332 (Follicular adenocarcinoma trabecular), 8335 (Follicular carcinoma, minimally invasive), and 8339 (Follicular thyroid carcinoma (FTC), encapsulated angioinvasive).

Exclusion criteria

(1). Absence of T stage information or designation as T1, T2; (2). Missing surgery codes; (3). Cases not verified by histopathological analysis; (4). FTC not being the initial malignancy diagnosed in the patient; (5). Unknown survival duration or survival less than one month; (6). Presence of bilateral tumors.

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival (OS)	Up to 10 years post-diagnosis	Time from diagnosis until death from any cause.
Cancer-Specific Survival (CSS)	Up to 10 years post-diagnosis	Time from diagnosis to death specifically from follicular thyroid carcinoma.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026